Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE: Bevacizumab with Encorafenib and Cetuximab in BRAF V600E Metastatic Colorectal Cancer
NCT06411600Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Vall d'Hebron Institute of Oncology. Started May 2024; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06411600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411600.